Neuropathic pain occurs when nerves are damaged or irritated, often leading to persistent burning, tingling, or heightened sensitivity to touch. In this study, researchers investigated whether cannabigerol (CBG)—a non-intoxicating cannabinoid found in Cannabis sativa—could reduce pain responses in experimental models of both acute and chronic neuropathic pain. Using rodent models, scientists evaluated behavioral pain responses as well as biological changes within the spinal dorsal horn, an important region involved in processing pain signals. (PMC)

The results showed that orally administered CBG produced significant antinociceptive effects, meaning it reduced pain sensitivity in multiple tests. Animals treated with CBG demonstrated lower thermal and mechanical hypersensitivity after nerve injury, along with decreased activation of microglial cells—immune cells in the spinal cord that contribute to chronic pain. The study found that these effects were primarily linked to increased activity of the cannabinoid receptor type 2 (CB2) rather than CB1 receptors or other inflammatory signaling pathways, suggesting a targeted mechanism for pain modulation. (PMC)

Overall, the findings suggest that CBG may help regulate neuroinflammation and pain signaling through CB2 receptor pathways, supporting its potential as a future approach for managing neuropathic pain. Because the research was conducted in animal models, the authors emphasize that clinical trials in humans are needed to determine safety, dosing, and real-world effectiveness. (PubMed)

Source

Rezende B, et al. Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models (October 2025) Available through the National Library of Medicine (NIH): https://pmc.ncbi.nlm.nih.gov/articles/PMC12567403/